ArticleMedicine2025
Identification of biomarkers for endometriosis based on summary-data-based Mendelian randomization and machine learning.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endometriosis (EM) significantly impacts the quality of life, and its diagnosis currently relies on surgery, which carries risks and may miss early lesions. Noninvasive biomarkers are urgently needed for early diagnosis and personalized treatment. This study utilized the genome-wide association study dataset from FinnGen and performed Multi-marker Analysis of GenoMic Annotation (MAGMA) to identify genes significantly associated with EM. Differentially expressed genes (DEGs) were then analyzed, and an intersection selection was conducted to obtain the MAGMA-related DEGs. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to explore the biological functions of these genes. Summary-data-based Mendelian randomization was used to identify potential risk and protective genes. Subsequently, a machine learning model was used to further select key biomarkers. Single-cell RNA sequencing and consensus clustering were applied to analyze the expression of biomarkers and classify the EM samples into subgroups. Immune infiltration analysis was conducted to evaluate the molecular characteristics of these subgroups. MAGMA analysis identified 2832 genes significantly associated with EM, while 3055 DEGs were detected. Intersection analysis resulted in 437 MAGMA-related DEGs. Summary-data-based Mendelian randomization analysis identified 10 candidate genes, and after further selection using a machine learning model, three core biomarkers were validated: adenosine kinase, enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase, and CCR4-NOT transcription complex subunit 7. Single-cell RNA sequencing revealed the expression patterns of these biomarkers. Consensus clustering analysis classified 77 EM samples into two subgroups, with immune infiltration analysis showing significant differences in immune cell composition among the subgroups. This study successfully identified three core biomarkers for EM: adenosine kinase, enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase, and CCR4-NOT transcription complex subunit 7, which exhibit protective roles in EM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.